ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,127.79
1.26%
US Tech 100
17,446.00
2.17%
Dow Jones
38,675.68
1.18%
Brent Oil
82.765
0.00%
Bitcoin
63,708.65
1.30%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. KalVista Pharmaceuticals Inc (KALV) Quote

KalVista Pharmaceuticals Inc

KalVista Pharmaceuticals Inc (KALV)

NASDAQ
12.13
-0.04
(-0.33%)
Closed May 04 4:00PM
Delayed by 15 minutes
12.13
0.00
(0.00%)
After Hours: 4:35PM
Delayed by 15 minutes

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
12.13
Bid
9.99
Ask
12.35
Volume
199,657
11.955 Day's Range 12.48
7.21 52 Week Range 16.88
Market Cap
512.588M
Previous Close
12.17
Open
12.24
Last Trade
1
@
12.18
Last Trade Time
Financial Volume
$ 2,405,793
VWAP
12.0496
Average Volume (3m)
802,639
Shares Outstanding
42,188,296
Dividend Yield
-
PE Ratio
-5.52
Earnings Per Share (EPS)
-2.2
Revenue
-
Net Profit
-92.91M

About KalVista Pharmaceuticals Inc

KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angio... KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.kalvista.com
Headquarters
Dover, Delaware, USA
Founded
1970
KalVista Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker KALV. The last closing price for KalVista Pharmaceuticals was $12.17. Over the last year, KalVista Pharmaceuticals shares have traded in a share price range of $ 7.21 to $ 16.88.

KalVista Pharmaceuticals currently has 42,188,296 shares outstanding. The market capitalization of KalVista Pharmaceuticals is $512.59 million. KalVista Pharmaceuticals has a price to earnings ratio (PE ratio) of -5.52.

KALV Latest News

More News

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted ten newly-hired employees inducement options to purchase an...

May 02 2024
Business Wire

KalVista Pharmaceuticals Highlights Strategic Plans for Coming Fiscal Year

- Regulatory filings planned for US, EU, UK and Japan to enable multiple 2025 commercial launches – - Development strategy refined for oral Factor XIIa program – - Organizational focus to drive...

May 01 2024
Business Wire

KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors...

April 22 2024
Business Wire

KalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare Conference

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors...

April 03 2024
Business Wire

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted nine newly-hired employees inducement options to purchase...

April 02 2024
Business Wire

KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas

– Delays in treating attacks lead to increased anxiety, quality of life issues, higher frequency of returning attacks, and suboptimal clinical outcomes in both on-demand and prophylaxis patients...

March 18 2024
Business Wire

KalVista Pharmaceuticals Awarded UK Promising Innovative Medicine (PIM) Designation for Sebetralstat

– Full EAMS designation would allow treatment of patients with sebetralstat prior to receiving a Marketing Authorization from UK – KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage...

March 12 2024
Business Wire

Form 8-K - Current report

March 11 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

March 11 2024
Edgar (US Regulatory)

KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update

- Sebetralstat Phase 3 KONFIDENT clinical trial met all endpoints and demonstrated a favorable safety profile as first oral on-demand therapy for hereditary angioedema - - CEO transition supports...

March 11 2024
Business Wire
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
11.6315.523809523810.512.5210.2636220111.71724455CS
418.9847259658611.1312.5210.1335179011.53637687CS
12-3.34-21.590174531415.4716.879310.1380263913.2607083CS
263.2536.59909909918.8816.887.2158966512.67043341CS
523.2236.13916947258.9116.887.2140916411.85243682CS
156-12.61-50.970088924824.7430.74.1231496711.95741077CS
260-10-45.187528242222.13454.1228790216.42760621CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
BENFBeneficient
$ 6.8001
(254.17%)
31.01M
SGBXSafe and Green Holdings Corporation
$ 5.49
(87.37%)
92.18M
SHOTWSafety Shot Inc
$ 0.45
(45.16%)
644
AIPArteris Inc
$ 8.185
(38.03%)
1.11M
RGFReal Good Food Company Inc
$ 0.85
(37.32%)
4.26M
MNDRMobile health Network Solutions
$ 3.33
(-84.91%)
18.76M
NUVOHoldco Nuvo Group DG Ltd
$ 2.00
(-57.54%)
1.04M
SPTSprout Social Inc
$ 28.82
(-40.15%)
13.47M
UNITUniti Group Inc
$ 4.441
(-26.35%)
21.07M
IPDNProfessional Diversity Network Inc
$ 1.29
(-24.12%)
662.59k
AAPLApple Inc
$ 183.38
(5.98%)
163.22M
SQQQProShares UltraPro Short QQQ
$ 11.08
(-5.94%)
154.59M
JAGXJaguar Health Inc
$ 0.3164
(7.91%)
142.47M
NKLANikola Corporation
$ 0.6526
(6.55%)
106.88M
SGBXSafe and Green Holdings Corporation
$ 5.49
(87.37%)
92.18M

KALV Discussion

View Posts
Monksdream Monksdream 1 month ago
KALV over $10
👍️0
Monksdream Monksdream 3 months ago
KALV new 52=week high
👍️0
clydesur clydesur 3 months ago
INSIDER PURCHASE / SYNDICATE

KALV - 10% OWNER Venrock Healthcare P 86,048 $14.618
👍️0
Monksdream Monksdream 3 months ago
KALV new 52 week high
👍️0
Monksdream Monksdream 4 months ago
KALV new 52 week high
👍️0
Femto99 Femto99 3 years ago
I would not even buy the shares at $20.
👍️0
Femto99 Femto99 3 years ago
All in puts!
👍️0
Stock_Barber Stock_Barber 3 years ago
Boom!

Killed it with puts today!

👍️0
ClayTrader ClayTrader 3 years ago
* * $KALV Video Chart 02-09-2021 * *

Link to Video - click here to watch the technical chart video

👍️0
Stock_Barber Stock_Barber 3 years ago
This company is a disaster...

👍️0
make it happen make it happen 3 years ago
The company is delinquent.
👍️0
make it happen make it happen 3 years ago
? lol

Profitability
Profit Margin 0.00%
Gross Profit (ttm) $-27.5M
EBITDA $-48.38M
Net Income Avi to Common (ttm) $-37.12M
Diluted EPS (ttm) -2.08

Book Value Per Share (mrq) $3.63

Going to keep diluting more and more
👍️0
make it happen make it happen 3 years ago
They are hemorrhaging money. Have pretty much zero revenue. They still have hundreds of millions to spend of your money until phase 3 and beyond.

Operating Margin (ttm) -905.50%

Management Effectiveness

Return on Assets (ttm) -32.60%
Return on Equity (ttm) -45.61%

Revenue  $5.4M
Revenue Per Share  $0.30

👍️0
TFMG TFMG 4 years ago


$KALV Kalvista Pharma Trend Break



Major Downtrend broken
Broken above 200ma
Volume increased
MACD reversed
RSi in bullish uptrend



👍️0
whytestocks whytestocks 5 years ago
News: $KALV KalVista Pharmaceuticals Appoints Daniel B. Soland to Board of Directors

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, announced today that Daniel Soland has been appointed to its Board of Directors effective immediately. Mr...

Find out more https://marketwirenews.com/news-releases/kalvista-pharmaceuticals-appoints-daniel-b-soland-to-board-of-directors-8035190.html
👍️0
whytestocks whytestocks 5 years ago
News: $KALV KalVista Pharmaceuticals to Present at Needham Healthcare Conference

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present at the Needham Healthcare Conference on Wednesday, April 10, 2019, a...

Read the whole news https://marketwirenews.com/news-releases/kalvista-pharmaceuticals-to-present-at-needham-healthcare-conference-7939130.html
👍️0
stocktrademan stocktrademan 5 years ago
KALV buy 28.87



normal chart







log chart






👍️0
whytestocks whytestocks 5 years ago
News: $KALV KalVista Pharmaceuticals Reports Fiscal Third Quarter Results

– Oral Hereditary Angioedema (HAE) Candidate KVD900 Phase 2 Trial Progressing – – Intravitreal Diabetic Macular Edema (DME) Candidate KVD001 Phase 2 Trial Completion Expected H2 2019 – – Oral Plasma Kallikrein Inhibitor Candidate KVD824 Dosi...

Read the whole news https://marketwirenews.com/news-releases/kalvista-pharmaceuticals-reports-fiscal-third-quarter-results-7846828.html
👍️0
countryrapper2000 countryrapper2000 6 years ago
Where is everyone?
👍️0
TheFinalCD TheFinalCD 7 years ago
$17.85 !!


KALV
👍️0
Lone Wolf Lone Wolf 7 years ago
Sniffer rocket ship today!! Wheeee.

KALV
👍️0
TheFinalCD TheFinalCD 7 years ago
$15.50 now ~ keep rollin



$KALV
👍️0
kondziu kondziu 7 years ago
http://m.nasdaq.com/article/sv-life-sciences-advisers-llc-buys-kalvista-pharmaceuticals-sells-raptor-pharmaceutical-cm744623
👍️0
Warchest Warchest 7 years ago
$8.25 now ~ keep rollin
👍️0
ming1234 ming1234 7 years ago
any positive news and volume will move this north
👍️0
Warchest Warchest 7 years ago
LIVE action starting !!!
👍️0
Warchest Warchest 7 years ago
watching close ~
👍️0
Toxic Avenger Toxic Avenger 7 years ago
The way this is dropping, there has to be a lawsuit over the sale of cash at 60% off.
Where are those ambulance chasing securities lawyers?
👍️0
MSparks6 MSparks6 7 years ago
So when will CBYL holders be issued KALV common stock?
👍️0
Toxic Avenger Toxic Avenger 7 years ago
CBYL is now KALV with a 1:14 reverse stock split.

Be very careful for the next few days as until all or most of the CBYL shares are converted to KALV, the only sellers will be private Kal Vista investors, those who bought after the symbol change and professionals. The price is likely to be high until existing CBYL retail holders can sell their shares. In addition, the existing CBYL shares will only represent 20% of the O/S. 80% will be held by the private investors in KVAL.
👍️0
Iam_in Iam_in 7 years ago
$6.00
👍️0
Iam_in Iam_in 7 years ago
New Ticker symbol now: KALV
👍️0
Iam_in Iam_in 7 years ago
Correction : $5.49 PM
👍️0
Iam_in Iam_in 7 years ago
WOW - look at this $0,89---> $4,60

New Ticker name now : KALV

look at NASDAQ - PM
👍️0
Toxic Avenger Toxic Avenger 7 years ago
Apparently the merger deal was approved by a huge margin.

Still don't get it.
👍️0
ClayTrader ClayTrader 7 years ago
* * $CBYL Video Chart 11-21-16 * *

Link to Video - click here to watch the technical chart video
👍️0
beginneer beginneer 7 years ago
Attempting to break 0.72. GL to holders
👍️0
beginneer beginneer 7 years ago
We'll see how this goes. Hopefully back to over a dollar.
👍️0
Toxic Avenger Toxic Avenger 7 years ago
CBYL continuing its upward momentum pre-market.
👍️0
ClayTrader ClayTrader 7 years ago
* * $CBYL Video Chart 11-18-16 * *

Link to Video - click here to watch the technical chart video
👍️0
beginneer beginneer 7 years ago
Oh okay. Im still up for it even if it is a merger. Good thing volume picked up today.
👍️0
Toxic Avenger Toxic Avenger 7 years ago
New buyer? They're not being bought, they're merging with another company and selling their cash at a steep discount.

Maybe the large shareholders decided it's better to take a smaller loss now by liquidating, than wait for a larger loss later and they're voting against the deal.

I can only hope!
👍️0
beginneer beginneer 7 years ago
Somethings fishy going on here. Why the sudden spike in volume? New buyer in sight?
👍️0
Toxic Avenger Toxic Avenger 7 years ago
Fun while it lasted.
👍️0
Toxic Avenger Toxic Avenger 7 years ago
Big bounce today. Anyone know why?
👍️0
Toxic Avenger Toxic Avenger 7 years ago
$700k / month for a company that has only a few execs and no business left???

No wonder they want to merge. If they liquidate, the execs all lose their gravy train.

Maybe that can be part of the class action suit.
👍️0
Toxic Avenger Toxic Avenger 7 years ago
Looks like an attempt to prevent the merger by some shareholders has failed. http://ih.advfn.com/p.php?pid=nmona&article=72839538&symbol=CBYL
👍️0
Toxic Avenger Toxic Avenger 7 years ago
Looks like an attempt to prevent the merger by some shareholders has failed. http://ih.advfn.com/p.php?pid=nmona&article=72839538&symbol=CBYL
👍️0
Toxic Avenger Toxic Avenger 7 years ago
Sadly, I don't think so.
👍️0
MSparks6 MSparks6 7 years ago
Any idea what the general consensus among shareholders is? We gonna be able to block this merger or is a 'no' vote futile?
👍️0

Your Recent History

NASDAQ
KALV
KalVista Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved